Amol Akhade/hiranandanihospital.org
Jan 23, 2025, 09:43
Amol Akhade: Interesting results on subcutaneous Amivantamab in CRC
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on LinkedIn:
“Amivantanab monotherapy (23 pts) and with Folfox/folferi (7 pts in right-sided Metastatic CRC, With prior 2 to 3 lines of therapy and prior anti-EGFR therapy allowed.
It shows good DCR (78%) with median pfs of 3.7 months and Median DOR 7.4 months for monotherapy.
Intresting results. Will like to see toxicity data in details.
As in NSCLC, will sub-cut amivantanab be better in CRC also?”
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 1, 2025, 10:57
Mar 1, 2025, 10:17
Mar 1, 2025, 09:24
Mar 1, 2025, 09:12
Mar 1, 2025, 08:45
Mar 1, 2025, 08:32
Mar 1, 2025, 08:26